Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy.

about

Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy.

Item

http://www.wikidata.org/entity/Q47142533

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Cost-effectiveness analysis of ...... öm macroglobulinemia in Italy.

@en

Cost-effectiveness analysis of ...... öm macroglobulinemia in Italy.

@nl

type

Item

label

Cost-effectiveness analysis of ...... öm macroglobulinemia in Italy.

@en

Cost-effectiveness analysis of ...... öm macroglobulinemia in Italy.

@nl

prefLabel

Cost-effectiveness analysis of ...... öm macroglobulinemia in Italy.

@en

Cost-effectiveness analysis of ...... öm macroglobulinemia in Italy.

@nl

P1476

Cost-effectiveness analysis of ...... öm macroglobulinemia in Italy.

@en

P2093

Andrea Aiello

http://www.w3.org/2001/XMLSchema#string

Anna D'Ausilio

http://www.w3.org/2001/XMLSchema#string

Francesca Randon

http://www.w3.org/2001/XMLSchema#string

Luca Laurenti

http://www.w3.org/2001/XMLSchema#string

Roberta Lo Muto

http://www.w3.org/2001/XMLSchema#string

P2860

Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

Ibrutinib in previously treated Waldenström's macroglobulinemia.

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.

Waldenström macroglobulinemia: my way.

Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis.

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

Waldenström's macroglobulinemia: clinical features, complications, and management.

Waldenstrom macroglobulinemia

P304

1393308

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/20016689.2017.1393308

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29201288

http://www.w3.org/2001/XMLSchema#string

P921

An Eadailt

P932

5700492

http://www.w3.org/2001/XMLSchema#string